Ractigen Therapeutics Secures Over $31 Million to Advance saRNA Pipeline
Ractigen Therapeutics has closed a financing round exceeding $31 million, led by Guozhong Capital and supported by several other investors. The funds will accelerate the development of RAG-01 in Phase 2 trials for non-muscle-invasive bladder cancer (NMIBC), advance systemic saRNA asset RAG-18 toward an IND filing for Duchenne muscular dystrophy, and progress CNS clinical candidate RAG-17 into Phase 2 trials for amyotrophic lateral sclerosis. The financing will also support the expansion of proprietary extrahepatic delivery platforms SCAD™ and LiCO™. Ractigen is pioneering small activating RNA (saRNA) therapeutics to enable gene activation, a novel approach in genetic medicine that targets promoter regions without altering DNA. This technology has shown potential for treating conditions such as cancer, metabolic diseases, and neuromuscular disorders by upregulating endogenous protein expression. The company's clinical-stage assets include RAG-01, which achieved promising results in Phase 1 trials with a high complete response rate among BCG-unresponsive patients. The investment underscores growing interest in RNA-based therapies that target previously undruggable genetic pathways.
Topics: biotech clinical development financing RNA therapeutics